Walgreen and Alliance Boots Custom Case Solution & Analysis

1. Evidence Brief

Financial Metrics

• Walgreen FY2011 revenue: 72.2 billion dollars.
• Walgreen FY2011 net income: 2.71 billion dollars.
• Alliance Boots FY2012 revenue: 23 billion pounds.
• Alliance Boots FY2012 EBITDA: 1.44 billion pounds.
• Transaction structure: Walgreen pays 6.7 billion dollars (4 billion cash and 83.4 million shares) for an initial 45 percent stake.
• Step 2 option: Right to purchase the remaining 55 percent in 2015 for 9.5 billion dollars plus assumption of Alliance Boots debt.
• Combined entity projected annual cost efficiencies: 1 billion dollars by year three.
• Walgreen store count: 8,210 locations across 50 US states.
• Alliance Boots reach: 3,330 retail stores and 370 distribution centers serving 170,000 pharmacies.

Operational Facts

• Walgreen lost its contract with Express Scripts in January 2012, resulting in an estimated 4 billion dollar revenue loss.
• Alliance Boots operates the leading pharmacy wholesaler in Europe and the largest pharmacy-led health and beauty retailer in the United Kingdom.
• Alliance Boots owns proprietary beauty brands including No7, Botanics, and Soap and Glory.
• The pharmaceutical industry is experiencing a massive wave of patent expirations, shifting volume toward lower-margin generics.
• Walgreen domestic growth is constrained by high store density and a maturing US market.

Stakeholder Positions

• Greg Wasson, CEO of Walgreen: Views the deal as a transformational step to become a global healthcare leader and offset domestic PBM pressure.
• Stefano Pessina, Executive Chairman of Alliance Boots: Largest shareholder of Alliance Boots; seeks a global platform and is willing to accept Walgreen equity as part of the payment.
• Walgreen Shareholders: Concerned about the high premium and the complexity of integrating a massive international operation while the domestic business recovers from the Express Scripts dispute.
• KKR: Private equity partner of Pessina looking for a structured exit from the 2007 leveraged buyout of Alliance Boots.

Information Gaps

• Specific debt covenants and interest rates for the 9.5 billion dollar second-step payment.
• Detailed breakdown of the 1 billion dollar efficiency target by specific business unit.
• Regulatory stance of US and EU antitrust authorities regarding combined generic purchasing power.
• Retention agreements for key Alliance Boots middle management during the 30-month interim period.

2. Strategic Analysis

Core Strategic Question

• How can Walgreen neutralize the bargaining power of Pharmacy Benefit Managers (PBMs) and combat domestic margin compression through global scale?
• Is a two-step international acquisition the most efficient way to secure generic procurement advantages compared to domestic consolidation?

Structural Analysis

The US retail pharmacy industry is trapped in a pincer movement. On the buyer side, PBM consolidation (exemplified by the Express Scripts-Medco merger) has decimated the bargaining power of retailers. On the supplier side, the shift to generics reduces gross profit dollars per prescription. Applying Porter Five Forces reveals that buyer power is the primary threat to Walgreen survival. The Alliance Boots deal is not a retail expansion; it is a backward integration play into the global supply chain. By combining volumes, the new entity becomes the largest single purchaser of generic drugs and prescription products in the world, shifting the power dynamic back toward the retailer.

Strategic Options

Preliminary Recommendation

Proceed with the Alliance Boots acquisition. The domestic US market no longer offers the growth or margin protection required to sustain Walgreen historical valuation. The combined entity creates a global champion with 11,000 stores and a distribution network that cannot be replicated by domestic peers like CVS. The procurement advantages in generics alone justify the premium, provided the integration focuses on the supply chain rather than just retail branding.

3. Implementation Planning

Critical Path

• Month 1-6: Establish the Bern, Switzerland-based joint venture to centralize global generic drug procurement. This is the primary driver of the 1 billion dollar efficiency target.
• Month 6-12: Pilot the introduction of Alliance Boots private label brands (No7, Botanics) into 500 high-traffic Walgreen locations to test US consumer uptake.
• Month 12-24: Harmonize IT systems for inventory management and global distribution tracking.
• Month 30: Exercise the option for the remaining 55 percent stake based on hitting predefined performance milestones in the procurement venture.

Key Constraints

• Management Bandwidth: The Walgreen leadership team is currently distracted by the Express Scripts fallout and domestic recovery.
• Financial Flexibility: The second step of the deal requires 9.5 billion dollars plus debt assumption, which will significantly increase the debt-to-equity ratio during a period of rising interest rates.
• Cultural Friction: The centralized, private-equity influenced style of Stefano Pessina may clash with the traditional, decentralized corporate culture of Walgreen.

Risk-Adjusted Implementation Strategy

The strategy utilizes the 30-month interim period as a de-facto integration laboratory. Rather than a total merger on day one, the focus remains on the procurement joint venture. This limits downside if the cultural integration fails, as the most significant financial benefits are derived from back-end supply chain coordination rather than front-end retail changes. Contingency plans include a phased rollout of the beauty brands to prevent inventory bloat if US consumer preferences differ from European trends.

4. Executive Review and BLUF

BLUF

Approve the Alliance Boots transaction. Walgreen must evolve from a domestic pharmacy into a global healthcare supply chain leader to survive the consolidation of Pharmacy Benefit Managers. The deal provides the necessary scale to dictate terms in the generic market and introduces high-margin private label products to the US. The two-step structure provides a 30-month window to validate cost-saving assumptions before committing to full ownership. This is a defensive necessity disguised as an offensive expansion.

Dangerous Assumption

The single most consequential premise is that the 1 billion dollar cost efficiency target can be realized primarily through procurement without triggering aggressive price retaliation from PBMs or regulatory intervention in the generic manufacturing sector. If PBMs simply adjust reimbursement rates downward to capture these savings, the margin benefit to Walgreen will be zero.

Unaddressed Risks

• Management Vacuum: There is a high probability that the 30-month gap between Step 1 and Step 2 creates a period of uncertainty for Alliance Boots executives, leading to a talent drain to competitors before Walgreen takes full control.
• Currency Volatility: With revenue now split between USD and GBP, and a major Swiss-based procurement hub, the company faces significant foreign exchange risk that could erode the value of the 1 billion dollar efficiency target.

Unconsidered Alternative

The team failed to fully evaluate a strategic divestiture of the Walgreen wholesale division to a player like AmerisourceBergen in exchange for a long-term, low-cost supply agreement. This would have provided immediate cash to repair the balance sheet without the immense integration risks of a cross-border merger.

Verdict

APPROVED FOR LEADERSHIP REVIEW